Tag: biopharma
Cue Biopharma Stock Analysis: Buy or Sell? Cash Burn, Dilution & Valuation
Cue Biopharma (CUE) is rated Sell as cash burn and dilution risk outweigh the promise of its Immuno-STAT pipeline. A 5.1x EV/revenue valuation and just $27.1 million of year-end cash leave little room for delay before clinical proof arrives.
Incyte Stock Analysis: Valuation, Patent Cliff, Cash Flow & Growth
Incyte (INCY) is rated Hold as strong cash generation and reasonable valuation are offset by the looming 2028 JAKAFI patent cliff. The company is profitable, but investors need OPZELURA, ZYNYZ and NIKTIMVO to scale fast enough to replace legacy franchise erosion.